Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.

Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling A, Paulson S.

Ann Oncol. 2020 Feb;31(2):202-212. doi: 10.1016/j.annonc.2019.11.003. Epub 2019 Dec 20. Review.

PMID:
31959337
2.

The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.

Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM.

Adv Med Sci. 2019 Dec 13;65(1):18-29. doi: 10.1016/j.advms.2019.10.002. [Epub ahead of print] Review.

PMID:
31841822
3.

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Malczewska A, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM.

Eur J Nucl Med Mol Imaging. 2019 Dec 14. doi: 10.1007/s00259-019-04601-3. [Epub ahead of print]

PMID:
31838581
4.

The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians.

Bodei L, Chiti A, Modlin IM, Scott AM, Schöder H.

J Nucl Med. 2019 Dec;60(12):1663-1664. doi: 10.2967/jnumed.119.232454. Epub 2019 Nov 15. No abstract available.

PMID:
31732675
5.

The use of Deep Learning and Neural Networks in Imaging - Welcome to the new Mathematical Milieu of Medicine.

Modlin IM, Kidd M, Drozdov IA, Bodei L.

Neuroendocrinology. 2019 Nov 7. doi: 10.1159/000504605. [Epub ahead of print]

6.

Neuroendocrine neoplasms of the small bowel and pancreas.

Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, Modlin I, Frilling A.

Neuroendocrinology. 2019 Sep 27. doi: 10.1159/000503721. [Epub ahead of print] Review.

7.

Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics.

Rahbar K, Bodei L, Morris MJ.

J Nucl Med. 2019 Nov;60(11):1504-1506. doi: 10.2967/jnumed.119.234054. Epub 2019 Aug 26.

PMID:
31451487
8.

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K.

Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.

PMID:
31440799
9.

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):6939-6947. doi: 10.1158/1078-0432.CCR-19-1026. Epub 2019 Aug 22.

PMID:
31439583
10.

An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-analysis.

Malczewska A, Kidd M, Matar S, Kos-Kudła B, Bodei L, Oberg K, Modlin IM.

Neuroendocrinology. 2019 Jul 1. doi: 10.1159/000500525. [Epub ahead of print] No abstract available.

PMID:
31266019
11.

A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation.

Kolasinska-Ćwikła A, Pęczkowska M, Ćwikła JB, Michałowska I, Pałucki JM, Bodei L, Lewczuk-Myślicka A, Januszewicz A.

J Clin Med. 2019 Jun 30;8(7). pii: E952. doi: 10.3390/jcm8070952.

12.

Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis.

Kidd M, Drozdov IA, Matar S, Gurunlian N, Ferranti NJ, Malczewska A, Bennett P, Bodei L, Modlin IM.

PLoS One. 2019 Jun 27;14(6):e0218592. doi: 10.1371/journal.pone.0218592. eCollection 2019.

13.

Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting.

Mahajan S, O'Donoghue J, Weber W, Bodei L.

J Nucl Med Radiat Ther. 2019;10(1). pii: 395. doi: 10.4172/2155-9619.1000395. Epub 2019 Feb 28.

14.

Blood Chromogranin A is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary NET/NET.

Matar S, Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk-Myślicka A, Filosso PL, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Kos-Kudła B, Ćwikła JB, Drozdov IA, Kidd M, Modlin IM.

Neuroendocrinology. 2019 Apr 16. doi: 10.1159/000500202. [Epub ahead of print]

PMID:
30995665
15.

NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging.

Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, Zajęcki W, Bodei L, Oberg KE, Kos-Kudła B.

Endocr Connect. 2019 Mar 1. pii: EC-19-0030.R1. doi: 10.1530/EC-19-0030. [Epub ahead of print]

16.

Time for a change and to adopt a novel molecular genomic approach in NETs.

Bodei L, Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR.

Nat Rev Clin Oncol. 2019 Apr;16(4):269-270. doi: 10.1038/s41571-019-0185-5. No abstract available.

PMID:
30809030
17.

Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.

Ulaner GA, Bodei L.

Clin Nucl Med. 2019 Apr;44(4):330-331. doi: 10.1097/RLU.0000000000002467.

18.

NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease.

Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk A, Filosso PL, Wójcik-Giertuga M, Rydel M, Zielińska-Leś I, Walter A, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Jamidar P, Ziora D, Czyżewski D, Kos-Kudła B, Ćwikła J.

Neuroendocrinology. 2019;108(3):219-231. doi: 10.1159/000497037. Epub 2019 Jan 17.

19.

Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus.

Bodei L, Herrmann K, Baum RP, Kidd M, Malczewska A, Modlin IM.

J Nucl Med. 2019 Jan;60(1):7-8. doi: 10.2967/jnumed.118.219386. No abstract available.

20.

Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.

Krebs S, Pandit-Taskar N, Reidy D, Beattie BJ, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, O'Donoghue JA.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685. doi: 10.1007/s00259-018-4193-y. Epub 2018 Oct 29.

PMID:
30374529
21.

Enchondroma of Tibia as Potential False-positive Finding on 68Ga-DOTATOC PET/CT Scan.

Mahajan S, Bodei L, Huicochea Castellanos S, Grewal RK.

Clin Nucl Med. 2019 Jan;44(1):e57-e59. doi: 10.1097/RLU.0000000000002360.

22.

Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease.

Malczewska A, Bodei L, Kidd M, Modlin IM.

J Clin Endocrinol Metab. 2019 Mar 1;104(3):867-872. doi: 10.1210/jc.2018-01804.

PMID:
30358858
23.

Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms.

Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):26-36. doi: 10.1159/000494258. Epub 2018 Oct 3. Review.

24.

Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.

Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L.

Oncologist. 2019 Jun;24(6):783-790. doi: 10.1634/theoncologist.2017-0623. Epub 2018 Aug 29.

25.

Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms.

Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O'Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):18-25. doi: 10.1159/000493319. Epub 2018 Aug 28. Review.

26.

The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors.

Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, Chung KM.

Endocrinol Metab Clin North Am. 2018 Sep;47(3):485-504. doi: 10.1016/j.ecl.2018.05.002. Review.

27.

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.

Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, Komissarova EV, Hagan EA, Bodei L, Clemons PA, Dela Cruz FS, Dhall D, Diolaiti D, Fraker DA, Ghavami A, Kaemmerer D, Karan C, Kidd M, Kim KM, Kim HC, Kunju LP, Langel Ü, Li Z, Lee J, Li H, LiVolsi V, Pfragner R, Rainey AR, Realubit RB, Remotti H, Regberg J, Roses R, Rustgi A, Sepulveda AR, Serra S, Shi C, Yuan X, Barberis M, Bergamaschi R, Chinnaiyan AM, Detre T, Ezzat S, Frilling A, Hommann M, Jaeger D, Kim MK, Knudsen BS, Kung AL, Leahy E, Metz DC, Milsom JW, Park YS, Reidy-Lagunes D, Schreiber S, Washington K, Wiedenmann B, Modlin I, Califano A.

Nat Genet. 2018 Jul;50(7):979-989. doi: 10.1038/s41588-018-0138-4. Epub 2018 Jun 18.

28.

Two Abdominal Masses Detected With 68Ga-DOTATATE PET/CT in a Patient With Necrolytic Migratory Erythema.

Grazia Giancipoli R, Khattar P, Bodei L.

Gastroenterology. 2018 Oct;155(4):e11-e13. doi: 10.1053/j.gastro.2018.05.045. Epub 2018 Jun 5. No abstract available.

PMID:
29883581
29.

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.

Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441. doi: 10.1007/s00259-018-4044-x. Epub 2018 May 21. Review.

30.

Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists.

Bodei L, Weber WA.

J Nucl Med. 2018 Jun;59(6):907-908. doi: 10.2967/jnumed.117.205161. Epub 2018 Mar 30. No abstract available.

31.

Modern Radiopharmaceutical Dosimetry Should Include Robust Biodistribution Reporting.

Kesner AL, Bodei L.

J Nucl Med. 2018 Oct;59(10):1507-1509. doi: 10.2967/jnumed.118.208603. Epub 2018 Mar 30.

32.

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Cwikla J, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169. doi: 10.1007/s00259-018-3967-6. Epub 2018 Feb 26.

33.

A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis.

Kidd M, Modlin IM, Drozdov I, Aslanian H, Bodei L, Matar S, Chung KM.

Oncotarget. 2017 Dec 29;9(6):7182-7196. doi: 10.18632/oncotarget.23820. eCollection 2018 Jan 23.

34.

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.

Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, Delgado-Bolton RC, Gabriel M.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):846-859. doi: 10.1007/s00259-018-3947-x. Epub 2018 Feb 16.

35.

Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.

Corrias G, Horvat N, Monti S, Basturk O, Lin O, Saba L, Bodei L, Reidy DL, Mannelli L.

Medicine (Baltimore). 2017 Dec;96(50):e9252. doi: 10.1097/MD.0000000000009252.

36.

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12.

PMID:
29234845
37.

The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.

Bodei L, Ćwikla JB, Kidd M, Modlin IM.

J Thorac Dis. 2017 Nov;9(Suppl 15):S1511-S1523. doi: 10.21037/jtd.2017.09.82. Review.

38.

Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.

Modlin IM, Kidd M, Filosso PL, Roffinella M, Lewczuk A, Cwikla J, Bodei L, Kolasinska-Cwikla A, Chung KM, Tesselaar ME, Drozdov IA.

J Thorac Dis. 2017 Nov;9(Suppl 15):S1458-S1473. doi: 10.21037/jtd.2017.03.82. Review.

39.

The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression.

Filosso PL, Kidd M, Roffinella M, Lewczuk A, Chung KM, Kolasinska-Cwikla A, Cwikla J, Lowczak A, Doboszynska A, Malczewska A, Catalano M, Zunino V, Boita M, Arvat E, Cristofori R, Guerrera F, Oliaro A, Tesselaar M, Buikhuisen W, Kos-Kudla B, Papotti M, Bodei L, Drozdov I, Modlin I.

Eur J Cardiothorac Surg. 2018 Mar 1;53(3):631-639. doi: 10.1093/ejcts/ezx386.

PMID:
29145657
40.

Somatostatin Receptor 2-Targeting Compounds.

Smit Duijzentkunst DA, Kwekkeboom DJ, Bodei L.

J Nucl Med. 2017 Sep;58(Suppl 2):54S-60S. doi: 10.2967/jnumed.117.191015. Review.

41.

Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.

Boas FE, Bodei L, Sofocleous CT.

J Nucl Med. 2017 Sep;58(Suppl 2):104S-111S. doi: 10.2967/jnumed.116.187229. Review.

42.

Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies.

Bodei L, Ambrosini V, Herrmann K, Modlin I.

J Nucl Med. 2017 Nov;58(11):1718-1726. doi: 10.2967/jnumed.116.186361. Epub 2017 Aug 17. Review.

43.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.

Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, Tiensuu Janson E, Ramage J; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):295-309. doi: 10.1159/000475526. Epub 2017 Apr 13. No abstract available.

PMID:
28402980
44.

The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas.

Pęczkowska M, Cwikla J, Kidd M, Lewczuk A, Kolasinska-Ćwikła A, Niec D, Michałowska I, Prejbisz A, Januszewicz A, Chiarelli J, Bodei L, Modlin I.

Eur J Endocrinol. 2017 Feb;176(2):143-157. Epub 2016 Nov 9.

PMID:
27913608
45.

Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.

Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):352. doi: 10.1007/s00259-016-3558-3. No abstract available.

PMID:
27807661
46.

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.

Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499. doi: 10.1007/s00259-016-3533-z. Epub 2016 Oct 4. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):352.

PMID:
27704193
47.

Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.

Bertani E, Fazio N, Radice D, Zardini C, Grana C, Bodei L, Funicelli L, Ferrari C, Spada F, Partelli S, Falconi M.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):981-989. Epub 2016 Sep 9.

PMID:
27613553
48.

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management.

Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM.

Endocr Connect. 2016 Sep;5(5):174-87. doi: 10.1530/EC-16-0043. Epub 2016 Aug 31.

49.

Myeloid neoplasms after chemotherapy and PRRT: myth and reality.

Bodei L, Modlin IM, Luster M, Forrer F, Cremonesi M, Hicks RJ, Ezziddin S, Kidd M, Chiti A.

Endocr Relat Cancer. 2016 Aug;23(8):C1-7. doi: 10.1530/ERC-16-0258. Epub 2016 Jun 28.

PMID:
27353035
50.

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.

Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP.

Semin Nucl Med. 2016 May;46(3):225-38. doi: 10.1053/j.semnuclmed.2015.12.003. Review.

PMID:
27067503

Supplemental Content

Support Center